Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina

University of Glasgow

Status and phase

Withdrawn

Phase 4

Conditions

Angina Pectoris

Diabetes Mellitus, Type 2

Treatments

Drug: Rosiglitazone

Drug: Gliclazide (Comparison drug)

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00225342

GlasUniRosiGlic

Eudract No. 2004-000943-40

Details and patient eligibility

About

The principle objective of the trial is to compare rosiglitazone to gliclazide in patients with type 2 diabetes mellitus and chronic stable angina to see how the subjects' angina status changes.

Angina status will be measured via exercise tolerance testing, 24-hour ECG testing and angina quality of life questionnaire.

Full description

Ischaemic heart disease is one of the main complications of type 2 diabetes mellitus, both in terms of morbidity and mortality. Reducing plasma glucose with hypoglycaemic agents has not been shown to improve cardiovascular mortality or morbidity. Chronic stable angina is a common problem in patients with type 2 diabetes mellitus.

We postulate that in subjects with uncontrolled type 2 diabetes mellitus (Hba1c >7.5%), on metformin therapy, and chronic stable angina that the addition of the insulin sensitiser, rosiglitazone to control their diabetes will improve their angina when compared to the addition of the hypoglycaemic agent gliclazide. This hypothesis is based on the fact that insulin resistance is an upstream mechanism common to both conditions.

We will randomise such patients to 3 months therapy of rosiglitazone or gliclazide for 3 months, comparing angina status before and after by way of full Bruce protocol exercise testing, 24 hour ST segment analysis and angina questionnaire.

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Chronic stable angina with ongoing symptoms. (The treatment goal being an improvement in symptoms)
Participants will have uncontrolled diabetes (Hba1c>7.5) on metformin monotherapy (so the diabetes is not over treated)
Participants will be diabetic for less than 8 years.

Exclusion criteria

Renal impairment (creatinine >130mmol/l)
Hepatic Impairment (ALT>70U/l, AST>80U/l)
Any clinical signs of heart failure
Physical disability precluding treadmill exercise tolerance testing
Abnormal resting ECG (left or right bundle-branch block, left or right ventricular hypertrophy, ventricular preexcitation, Q-wave myocardial infarction, digitalis therapy)
Women of childbearing potential
Women who are breastfeeding